Biophytis S.A.

ALBPS

FR0012816825

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 05:47:02 2024-04-19 am EDT			5-day change	1st Jan Change
0.0023 ^EUR	-4.17%		-11.54%	-54.90%

11:54am	Biophytis Changes ADR Ratio From 100 to 4,000 Shares	MT
Apr. 18	Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Biophytis S.A.

Biophytis Changes ADR Ratio From 100 to 4,000 Shares	05:54am	MT
Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity	Apr. 18	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	Apr. 16	MT
French Biotech Biophytis Files Patent Application for BIO101	Apr. 15	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
Biophytis: patent application filed in the field of obesity	Apr. 15	CF
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Apr. 12	MT
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	Apr. 11	MT
ADRs Close Lower; VIA Optronics AG Declines 30%	Apr. 10	DJ
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 10	MT
ADRs End Higher; Biophytis Climbs 30%	Apr. 09	DJ
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	Apr. 09	MT
Top Premarket Gainers	Apr. 09	MT
Biophytis launches clinical study in obesity	Apr. 09	CF
Biophytis Flags 'Significant Doubt' Over Ability to Continue Operations; to Launch Phase 2 Obesity Trial; Shares Rise Pre-Bell	Apr. 09	MT
Biophytis SA Launches OBA Phase 2 Clinical Study in Obesity with BIO101 (20-Hydroxyecdysone)	Apr. 08	CI
Biophytis S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	Apr. 08	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Apr. 03	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	Mar. 27	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	Mar. 26	MT

Biophytis S.A. is a biotechnology company in the clinical stage specialized in the development of drug candidates to slow degenerative processes and improve functional capacity in patients with age-related diseases, including respiratory failure in patients suffering from COVID-19. The company is located in Paris, France and Cambridge, Massachusetts.

Sector

Biotechnology & Medical Research

Calendar

2024-10-28 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOPHYTIS S.A.	-54.90%	2.93M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B
ARGENX SE	-1.25%	21.66B
BIONTECH SE	-18.35%	20.77B
GENMAB A/S	-8.38%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-26.84%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B